Philip Morris Grew 10.4%, but U.S. ZYN Stalled

Philip Morris crossed $11 billion of quarterly revenue for the first time. Q2 FY2026 revenue was $11.19 billion, up 10.4% reported and 7.6% organically from $10.14 billion a year earlier. Total shipments increased 2.5%, with smoke-free shipments up 7.5% and cigarettes up 1.1%. The composition mattered: international smoke-free revenue rose 14.2%, international combustible revenue rose 9.8%, and U.S. revenue declined 0.7%, according to the Q2 FY2026 earnings release.

Margins improved more quickly than revenue. The quarterly financial table shows gross margin rising to 68.4% from 67.7%, while operating margin increased to 40.5% from 36.6%. On the company's adjusted basis, gross margin expanded 0.7 percentage points to 68.5% and operating margin expanded 0.7 points to 42.6%. Pricing contributed $689 million of the $1.05 billion reported revenue increase, and marketing, administration and research costs were effectively flat at approximately $2.98 billion. That combination produced 22.0% reported operating-income growth and 12.4% adjusted growth.

Reported EPS moved in the opposite direction. Diluted EPS declined 7.7% to $1.80 from $1.95 because Philip Morris recorded a $511 million non-cash impairment of its deconsolidated Canadian affiliate RBH, equal to $0.33 per share. After adjustments, diluted EPS increased 15.2% to $2.20. The distinction is material: the impairment reduced the accounting value of an investment but did not reverse the quarter's underlying revenue or margin gains.

Free cash flow was $5.11 billion, compared with $3.06 billion in Q2 FY2025. Quarterly cash conversion can move with working capital, so one period should not be annualized, but the increase adds support to the earnings quality shown in the Q2 FY2026 Form 10-Q.

The weak point was the U.S. segment. ZYN shipments increased 1.8%, but offtake was flat to slightly higher and ZYN revenue was broadly stable. Total U.S. revenue declined 0.7%, gross profit fell 9.2%, and adjusted operating companies income declined 19.1% organically. Philip Morris attributed the gross-profit pressure to segment mix and higher manufacturing costs associated with expanding its footprint. New ZYN ULTRA variants began shipping in June, with more nicotine strengths planned for the third quarter, but those launches had little time to affect Q2.

The quarter strengthened the central operating argument: smoke-free growth can support higher group margins rather than simply replace profitable cigarette sales. International smoke-free shipments rose 8.0%, revenue increased 14.2%, and gross profit increased 17.1%. IQOS shipment volume grew 7.6%, while VEEV shipments rose 55.1%. International smoke-free adjusted gross margin reached 70.1%, 1.8 percentage points above the prior-year period.

The growth was also geographically broad enough to absorb identifiable disruptions. IQOS adjusted in-market sales declined in Japan following an excise-driven price increase and faced a characterizing-flavor ban in Poland. Excluding Japan and Poland, adjusted in-market sales grew 10%. Outside Europe and Japan, growth was 14.4%. That breadth reduces dependence on any single IQOS market, although regulation remains capable of changing category economics quickly.

Combustibles provided the other half of the result. International cigarette volume increased only 1.1%, but a 10.0% pricing contribution helped lift international combustible revenue 9.8% and gross profit 11.5%. This is favorable for current earnings, yet it also identifies what must continue: Philip Morris needs enough pricing power to offset long-term cigarette pressure while smoke-free products become a larger profit source.

The U.S. performance prevents an unambiguously bullish conclusion. ZYN's quarterly stabilization was better than the first-quarter inventory disruption, but broadly flat revenue in a growing category suggests competition and portfolio positioning are constraining near-term growth. Management plans to accelerate second-half U.S. investment to support the expanded ZYN lineup and prepare for IQOS ILUMA. That spending may strengthen the franchise, but it also means the segment's profit recovery could lag its revenue recovery.

Guidance offered limited new information. Philip Morris maintained organic revenue growth of 5% to 7% and organic operating-income growth of 7% to 9%. It improved the shipment assumption to broadly stable or slightly growing total volume and narrowed the expected cigarette decline to 2%–3%. However, adjusted EPS of $8.26–$8.41 was updated only for currency, with the expected favorable currency benefit reduced to $0.15 from $0.20. The quarter improved confidence in execution rather than changing the full-year earnings destination.

With no prior SageNoodle coverage, this report establishes rather than revises fair value. The base case applies a 21.0x multiple to the $8.34 midpoint of management's FY2026 adjusted EPS forecast, producing approximately $175 per share. The multiple recognizes double-digit adjusted EPS growth, strong returns on capital and improving smoke-free economics, while remaining below the current trailing P/E of 27.3x because leverage, regulation and execution risk warrant a discount.

The bear case uses $8.11 of EPS, equal to the bottom of management's currency-neutral adjusted range, and an 18.5x multiple. That produces $150 per share and represents weaker U.S. momentum, less pricing leverage and a slower margin transition. The bull case applies 25.0x to the $8.41 top end of reported adjusted guidance, producing $210 per share. That outcome requires international smoke-free growth to remain strong, ZYN to reaccelerate and margin gains to persist despite higher U.S. investment.

At $189.77, the shares trade 8.4% above the $175 base-case value. That falls within SageNoodle's fairly valued band, but the asymmetry is not especially favorable: the price is closer to the bull value than to the bear value. The 4.3% trailing free-cash-flow yield provides more valuation support than the earnings multiple, yet net debt of $44.1 billion and no planned 2026 repurchases limit the immediate capital-allocation offset. EV/EBITDA was not disclosed in the supplied data.

The thesis would improve if the U.S. weakness proves temporary. ZYN now has additional strengths and formats, and 20 flagship variants received Modified Risk Tobacco Product authorization from the FDA. If those changes restore volume growth without sustained discounting or disproportionate marketing expenditure, the bull-case multiple would become more defensible.

The more damaging outcome would be simultaneous pressure on smoke-free growth and combustible pricing. Flavor restrictions in Poland and the excise-driven adjustment in Japan show how regulation and taxation can interrupt category momentum. Meanwhile, the quarter's $689 million pricing contribution demonstrates how much group growth still relies on price. A deterioration in consumer affordability or more discriminatory excise structures could weaken both pillars.

Leverage remains relevant even with high profitability. FY2025 net debt was $44.1 billion and equity was negative, while management is targeting net debt to adjusted EBITDA near 2.0x by year-end 2026. Cash generation supports that objective, but acquisitions, currency movements, litigation or weaker operating cash flow could slow deleveraging.

Finally, reported and adjusted earnings may continue to diverge. The RBH impairment did not consume cash this quarter, but it reflects a real reduction in the assessed value of the Canadian investment. Repeated impairments, restructuring charges or regulatory settlements would make adjusted EPS a less complete representation of the economics. Q2 was operationally strong; the current valuation leaves limited room for those exceptions to become recurring.